Suppr超能文献

壳聚糖-硅氧烷杂化水凝胶的制备及其体外细胞相容性

Preparation and in vitro cytocompatibility of chitosan-siloxane hybrid hydrogels.

作者信息

Shirosaki Yuki, Hirai Masashi, Hayakawa Satoshi, Fujii Eiji, Lopes Maria A, Santos José D, Osaka Akiyoshi

机构信息

Frontier Research Academy for Young Researchers, Kyushu Institute of Technology, Hibikino, Wakamatsu-ku, Kitakyushu, 808-0196, Japan.

出版信息

J Biomed Mater Res A. 2015 Jan;103(1):289-99. doi: 10.1002/jbm.a.35171. Epub 2014 Apr 3.

Abstract

Injectable systems can be used in minimally invasive surgical applications. Although chitosan-glycerophosphate hydrogel systems are biodegradable and biocompatible, the long periods of time required for their effective gelation have severely limited their clinical application. The challenges currently facing researchers in this field are therefore focused on shortening the gelation time and biocompatibility of these materials to develop hydrogels suitable for clinical application. Chitosan and γ-glycidoxypropyltrimethoxysilane (GPTMS) hybrids have recently demonstrated good cytocompatibility with respect to human osteoblastic cells (MG63) and human bone marrow cells. Although these precursor sols could form gels under physiological conditions, they required neutralization with a sodium hydroxide solution. In this study, the chitosan-GPTMS hybrid systems were neutralized with glycerophosphate to prepare injectable hydrogels. The results revealed that the gelation time of the hydrogels could be controlled by the amount of GPTMS in the precursor sols. The in vitro cytocompatibility of the hydrogels were evaluated in terms of the proliferation of MG63 cells cultured either directly onto the hydrogels or indirectly onto the cell culture plate under a hydrogel insert. In the former case, the cells showed good attachment and proliferated for up to 7 days. Similar results were observed in the in direct culture. These results suggest that this new chitosan-GPTMS hydrogel could potentially be used as an injectable biomaterial in clinical applications.

摘要

可注射系统可用于微创手术应用。尽管壳聚糖 - 甘油磷酸盐水凝胶系统具有生物可降解性和生物相容性,但其有效凝胶化所需的长时间严重限制了它们的临床应用。因此,该领域研究人员目前面临的挑战集中在缩短这些材料的凝胶化时间和提高生物相容性,以开发适合临床应用的水凝胶。壳聚糖与γ-缩水甘油氧基丙基三甲氧基硅烷(GPTMS)的杂化物最近已证明对人成骨细胞(MG63)和人骨髓细胞具有良好的细胞相容性。尽管这些前体溶胶在生理条件下可以形成凝胶,但它们需要用氢氧化钠溶液中和。在本研究中,壳聚糖 - GPTMS杂化系统用甘油磷酸盐中和以制备可注射水凝胶。结果表明,水凝胶的凝胶化时间可以通过前体溶胶中GPTMS的量来控制。通过直接培养在水凝胶上或间接培养在水凝胶插入物下的细胞培养板上的MG63细胞的增殖来评估水凝胶的体外细胞相容性。在前一种情况下,细胞显示出良好的附着并增殖长达7天。在间接培养中也观察到类似结果。这些结果表明,这种新型壳聚糖 - GPTMS水凝胶有可能在临床应用中用作可注射生物材料。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验